Want to join the conversation?
$DAL 2Q15 Call: On the topic of hedging, Paul answered that DAL has not actually materially changed its hedge profile since February. He mentioned that there is not any urgency and DAL is not changing the course of action and is content with where the book sits right now.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.